This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Welcome to Reed Smith's viewpoints — timely commentary from our lawyers on topics relevant to your business and wider industry. Browse to see the latest news and subscribe to receive updates on topics that matter to you, directly to your mailbox.
| 1 minute read

Unanswered questions in wake of Dobbs opinion - radiology is not exempt

The U.S. Supreme Court decision in Dobbs v. Jackson Women’s Health Organization, overturning Roe v. Wade and Planned Parenthood of Southeast Pennsylvania v. Casey, indicated that the Court was leaving regulation of abortion up to the states. Our law firm has convened a working group to address potential implications of this opinion for our clients across the various sectors in health care and life sciences industry space.

This working group, comprised of many of my Reed Smith Life Sciences Health Industry Group colleagues, has prepared an informative series of “Unanswered Questions” that identify many of the issues the Dobbs decision could raise for numerous life science and health care entities. Through these questions, the working group explores how the decision will trigger changes to many state laws, and the complexity that clients with national / multi-state operations will need to cope with in order to comply with likely conflicting laws and regulations. 

The compilation of unanswered questions published to date include those relating to pharmacies, health care providers, fertility, employee benefits, personal information and privacy, and employment. 

Radiology is not exempt. It is no longer rare for radiology groups to have employed or contracted with radiologists who practice in multiple states. What are the ramifications to radiologists who are licensed in states that restrict and states that do not restrict reproductive health services? What is the impact on radiology groups in those circumstances?

Commend these important issues to your attention.

Reed Smith will continue to monitor developments and provide updates in response to the Dobbs opinion.


health care & life sciences, dobbs